Drugs / VAC-3S
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02390466 | Apr 2015 → Apr 2017 | HIV infectious disease | InnaVirVax | Unknown | No outcome recorded |
| Phase 1/2 | NCT01549119 | Feb 2012 → Feb 2013 | HIV infectious disease | InnaVirVax | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02041247 Comparator | Jan 2014 → Sep 2015 | HIV infectious disease | InnaVirVax | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VAC-3S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01549119 ↗ |
| Modality | Vaccine | “therapeutic vaccine candidate VAC-3S” NCT01549119 ↗ |
| Route | Intramuscular | “VAC-3S is administered via intra-muscular route in the arm.” NCT02041247 ↗ |